Publicaciones en colaboración con investigadores/as de Centro de Investigaciones Biológicas (18)

2021

  1. Methylsulfanylpyridine based diheteroaryl isocombretastatin analogs as potent anti-proliferative agents

    European Journal of Medicinal Chemistry, Vol. 209

  2. New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

    International Journal for Parasitology: Drugs and Drug Resistance, Vol. 16, pp. 45-64

  3. New indolesulfonamide derivatives targeting the colchicine site of tubulin: synthesis, anti-tumour activity, structure–activity relationships, and molecular modelling

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 2025-2044

2020

  1. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring

    Bioorganic Chemistry, Vol. 98

2019

  1. Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target

    Medicinal Research Reviews, Vol. 39, Núm. 3, pp. 775-830

  2. Imidazo[2,1-a]isoindole scaffold as an uncharted structure active on Leishmania donovani

    European Journal of Medicinal Chemistry, Vol. 182

  3. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors

    Molecules (Basel, Switzerland), Vol. 24, Núm. 23

2018

  1. Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells

    European Journal of Medicinal Chemistry, Vol. 158, pp. 167-183

2016

  1. Dietary and microbiome factors determine longevity in Caenorhabditis elegans

    Aging, Vol. 8, Núm. 7, pp. 1513-1539

2015

  1. Mechanisms of action of substituted β-amino alkanols on leishmania donovani

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 2, pp. 1211-1218

2014

  1. Impaired wound repair in adult endoglin heterozygous mice associated with lower NO bioavailability

    Journal of Investigative Dermatology, Vol. 134, Núm. 1, pp. 247-255

2013

  1. Endowing indole-based tubulin inhibitors with an anchor for derivatization: Highly potent 3-substituted indolephenstatins and indoleisocombretastatins

    Journal of Medicinal Chemistry, Vol. 56, Núm. 7, pp. 2813-2827

2012

  1. Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins

    Journal of Medicinal Chemistry, Vol. 55, Núm. 15, pp. 6724-6737

2006

  1. Endoglin regulates cyclooxygenase-2 expression and activity

    Circulation Research, Vol. 99, Núm. 3, pp. 248-256

  2. Reduced angiogenic responses in adult endoglin heterozygous mice

    Cardiovascular Research, Vol. 69, Núm. 4, pp. 845-854

2005

  1. Temporal changes in renal endoglin and TGF-β1 expression following ureteral obstruction in rats

    Journal of Physiology and Biochemistry, Vol. 61, Núm. 3, pp. 457-467

2001

  1. Up-regulation of endoglin, a TGF-β-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction

    Nephrology Dialysis Transplantation, Vol. 16, Núm. SUPPL. 1, pp. 34-39

2000

  1. Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4

    Bioorganic and Medicinal Chemistry Letters, Vol. 10, Núm. 22, pp. 2549-2551